APAC expansion strengthens global biotech growth plan

Expanded regional partnerships advance customer access and technical support for single-cell analysis technologies

Sphere Bio is strengthening its footprint across Asia-Pacific with the appointment of five new distribution partners, a move aimed at accelerating its commercial growth and enhancing local access to its advanced single-cell analysis solutions.

The company - known for its picodroplet-based microfluidics platforms - has signed new agreements with 1st PhileKorea (South Korea), As One Corporation (Japan), Decode Science (Australia and New Zealand), Everlife Research Instruments (Singapore), and Premas Life Sciences (India and Bangladesh). These join existing partners in China, Hong Kong, Taiwan, Thailand, and other key markets.

The expanded network supports Sphere Bio’s global scale-up strategy, ensuring faster delivery, local product expertise, and technical support across APAC. It also facilitates broader adoption of its technology portfolio, including the newly launched Cyto-Mine® Chroma platform and advanced functional assays.

“This is a critical step as we meet growing demand in high-potential markets,” said Dale Levitzke, CEO. “Partnering with established regional leaders helps us bring single-cell analysis closer to scientists driving discovery.”

Jay Manikandan, VP Commercial (APAC), added, “We’re investing not just in sales reach but in regional customer success. Local expertise will play a key role in supporting adoption and driving deeper engagement with our technologies.”

More information online